HuGE Literature Finder
Records
1
-
3
Mutational signature 3 detected from clinical panel sequencing is associated with responses to olaparib in breast and ovarian cancers. Clinical cancer research : an official journal of the American Association for Cancer Research 2022 Sep . Batalini Felipe, Gulhan Doga C, Mao Victor, Tran Antuan, Polak Madeline, Xiong Niya, Tayob Nabihah, Tung Nadine M, Winer Eric P, Mayer Erica L, Knappskog Stian, Lønning Per Eystein, Matulonis Ursula A, Konstantinopoulos Panagiotis A, Solit David B, Won Helen, Eikesdal Hans Petter, Park Peter J, Wulf Gerburg |
Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2015 May 26 (5): 914-20. Monk B J, Ghatage P, Parekh T, Henitz E, Knoblauch R, Matos-Pita A S, Nieto A, Park Y C, Cheng P S, Li W, Favis R, Ricci D, Poveda |
Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study. International journal of cancer. Journal international du cancer 2003 Sep 106 (4): 588-93. de Sanjosé Silvia, Léoné Mélanie, Bérez Victoria, Izquierdo Angel, Font Rebeca, Brunet Joan M, Louat Thierry, Vilardell Loreto, Borras Joan, Viladiu Pau, Bosch F Xavier, Lenoir Gilbert M, Sinilnikova Olga |
- Page last reviewed:Feb 1, 2023
- Page last updated:Feb 07, 2023
- Content source: